Leerink Positive on Ophthotech (OPHT) Amid Regeneron (REGN) Failure
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/18/2024
- Stocks end near flat as investors assess earnings, data
- Netflix Q1 earnings top estimates on blowout subscriber growth
- Taiwan Semi (TSM) Q1 profit beats expectations on AI demand
- Stocks have priced in much of the 2024 optimism - Wells Fargo
- Intuitive Surgiical (ISRG) beats earnings, revenue expectations in Q1
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- ICZOOM Group (IZM) Discloses Request to Withdraw Registration Statement on Form F-1
- Alaska Airlines flights resume after being grounded over aircraft system issue
- Frontier Communications (FYBR) says third party had gained unauthorized access to portions of its information technology environment
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
- After-hours movers: United Airlines, J.B. Hunt, and more
Leerink Partners Reiterates Outperform on Regeneron (REGN)
October 3, 2016 8:48 AM EDTLeerink Partners reiterated an Outperform rating and $530.00 price target on Regeneron Pharma (NASDAQ: REGN) after Regeneron and Sanofi reported full results from the two Phase III SOLO studies.
Analyst Geoffrey Porges commented, "We reiterate our bullish view for dupilumab after Regeneron and Sanofi (SNY, OP) reported full results from the two Phase III SOLO studies in... More
Roth Capital Affirms Regeneron (REGN) at 'Buy' Following Eylea Phase 2 Data in Wet-AMD
September 30, 2016 10:16 AM EDTRoth Capital reaffirms Regeneron (Nasdaq: REGN) at Buy with a price target of $520 following... More
Ophthotech Corp (OPHT) on Watch After Regeneron (REGN) Reports Eylea/Rinucumab Combo Data
September 30, 2016 8:05 AM EDTOphthotech Corp (NASDAQ: OPHT) was in focus Friday morning after Regeneron (NASDAQ: REGN) announced topline results from its Phase 2 CAPELLA study evaluating Eylea (aflibercept) co-formulated with rinucumab in patients with neovascular age-related macular degeneration (wet AMD).
Ophthotech traded lower pre-market.
... More
